ArticlePharmacoEconomics2010

US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

Anita Brogan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.